216.73.216.164
dgid:
enl:
npi:0
/nas/content/live/oph360live/wp-content/themes/rd360/archive.php
Home Extended dosing with faricimab offers non-inferior vision gains in DME, wet AMD

Diabetic Macular Edema

VERONA 24-week results: efficacy of vorolanib intravitreal insert in DME

Watch Now
By rd360stg
Preoperative anti-VEGF therapy reduces swelling after cataract surgery in diabetic eyes
By rd360stg
Combining laser and anti-VEGF therapy may improve outcomes in diabetic macular edema
By rd360stg
Updates from Angiogenesis 2025 meeting detail recent outcomes for EYP-1901 in AMD and DME
By rd360stg
EyePoint reports favorable 6-month results for Duravyu in Phase 2 trial for DME
By rd360stg
FDA approves Susvimo as first continuous delivery treatment for diabetic macular edema
By rd360stg
Global survey highlights challenges in managing diabetic macular edema
By rd360stg
PHOTON trial assesses aflibercept 8 mg for diabetic macular edema
By rd360stg
Modeling study observes extended durability of aflibercept 8 mg
By rd360stg
Long-term costs of diabetic macular edema significantly exceed those of diabetes alone
By rd360stg
Study finds age impacts effectiveness of anti-VEGF treatments for diabetic macular edema
By rd360stg
Study finds optimal timing for steroid switch in DME treatment
By rd360stg
Faricimab matches aflibercept in VA improvement, outperforms in reducing retinal thickness for DME
-Advertisement-
-Advertisement-

Contact Info

Grandin Library Building
Six Leigh Street
Clinton, New Jersey 08809

+908-505-8899
[email protected]

Social Links

© 2025 Ophthalmology 360® is a trademark of International Healthcare Media, LLC. All rights Reserved
-Advertisement-
-Advertisement-